4502
Takeda Pharmaceutical Company Limited
武田薬品工業
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
3,569,006
Mar 2023
4,027,478
Mar 2024
4,263,762
Mar 2025
4,581,551
Mar 2026
4,505,720
Operating profit(million JPY)
Mar 2022
460,844
Mar 2023
490,505
Mar 2024
214,075
Mar 2025
342,586
Mar 2026
6,217
Operating profit margin(%)
Mar 2022
12.91
Mar 2023
12.18
Mar 2024
5.02
Mar 2025
7.48
Mar 2026
0.14
Profit before tax(million JPY)
Mar 2022
302,571
Mar 2023
375,090
Mar 2024
52,791
Mar 2025
175,084
Mar 2026
-142,355
Profit(million JPY)
Mar 2022
230,059
Mar 2023
317,017
Mar 2024
144,067
Mar 2025
107,928
Mar 2026
-152,390
Total assets(million JPY)
Mar 2022
13,178,018
Mar 2023
13,957,750
Mar 2024
15,108,792
Mar 2025
14,248,344
Mar 2026
15,511,506
Cash and cash equivalents(million JPY)
Mar 2022
849,695
Mar 2023
533,530
Mar 2024
457,800
Mar 2025
385,113
Mar 2026
595,054
Cash flows from operating activities(million JPY)
Mar 2022
1,123,105
Mar 2023
977,156
Mar 2024
716,344
Mar 2025
1,057,182
Mar 2026
1,041,431
Cash flows from investing activities(million JPY)
Mar 2022
-198,125
Mar 2023
-607,102
Mar 2024
-463,862
Mar 2025
-367,060
Mar 2026
-369,141
Cash flows from financing activities(million JPY)
Mar 2022
-1,070,265
Mar 2023
-709,148
Mar 2024
-354,416
Mar 2025
-751,425
Mar 2026
-496,820
Return on equity(%)
Mar 2022
4.2
Mar 2023
5.3
Mar 2024
2.1
Mar 2025
1.5
Mar 2026
-2.1
Equity ratio(%)
Mar 2022
43.1
Mar 2023
45.5
Mar 2024
48.1
Mar 2025
48.7
Mar 2026
47.9
Earnings per share(JPY per share)
Mar 2022
147.14
Mar 2023
204.29
Mar 2024
92.09
Mar 2025
68.36
Mar 2026
-96.75
Net assets per share(JPY per share)
Mar 2022
3,665.61
Mar 2023
4,087.49
Mar 2024
4,635.56
Mar 2025
4,407.01
Mar 2026
4,702.66
Dividend per share(JPY per share)
Mar 2022
180
Mar 2023
180
Mar 2024
188
Mar 2025
196
Mar 2026
200
Payout ratio(%)
Mar 2022
122.33
Mar 2023
88.11
Mar 2024
204.15
Mar 2025
286.72
Mar 2026
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.